1-N-(2,3-diaminopropyl)-4-imidazo[1,2-a]pyridin-8-yl-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide
C17H20N10O4S2 — CID 135310687
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-N-(2,3-diaminopropyl)-4-imidazo[1,2-a]pyridin-8-yl-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide
1-N-(2,3-diaminopropyl)-4-imidazo[1,2-a]pyridin-8-yl-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide (PubChem CID 135310687) has the molecular formula C17H20N10O4S2 and a molecular weight of 492.55 g/mol. Its IUPAC name is 1-N-(2,3-diaminopropyl)-4-imidazo[1,2-a]pyridin-8-yl-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide.
Molecular Properties
| Compound Name | 1-N-(2,3-diaminopropyl)-4-imidazo[1,2-a]pyridin-8-yl-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide |
|---|---|
| PubChem CID | 135310687 |
| Molecular Formula | C17H20N10O4S2 |
| Molecular Weight | 492.55 g/mol |
| Exact Mass | 492.11 |
| IUPAC Name | 1-N-(2,3-diaminopropyl)-4-imidazo[1,2-a]pyridin-8-yl-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide |
| SMILES | NCC(N)CNS(=O)(=O)c1ccc(-c2cccn3ccnc23)c(-c2nn[nH]n2)c1S(N)(=O)=O |
| InChI | InChI=1S/C17H20N10O4S2/c18-8-10(19)9-22-33(30,31)13-4-3-11(12-2-1-6-27-7-5-21-17(12)27)14(15(13)32(20,28)29)16-23-25-26-24-16/h1-7,10,22H,8-9,18-19H2,(H2,20,28,29)(H,23,24,25,26) |
| InChIKey | UPTYLORMCUHQQZ-UHFFFAOYSA-N |
| XLogP | -1.61 |
| TPSA | 230.13 Ų |
| H-Bond Donors | 5 |
| H-Bond Acceptors | 11 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 492.55 |
| LogP ≤ 5 | -1.61 |
| H-Bond Donors ≤ 5 | 5 |
| H-Bond Acceptors ≤ 10 | 11 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 135310687 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.